State of Alaska Department of Revenue boosted its holdings in Boston Scientific Corporation (NYSE:BSX) by 349.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 177,300 shares of the medical equipment provider’s stock after purchasing an additional 137,890 shares during the period. State of Alaska Department of Revenue’s holdings in Boston Scientific were worth $4,393,000 as of its most recent SEC filing.
Other hedge funds have also bought and sold shares of the company. Sit Investment Associates Inc. boosted its position in Boston Scientific by 37.8% in the third quarter. Sit Investment Associates Inc. now owns 141,710 shares of the medical equipment provider’s stock worth $4,134,000 after purchasing an additional 38,855 shares during the last quarter. Greenwood Capital Associates LLC raised its stake in shares of Boston Scientific by 71.7% in the third quarter. Greenwood Capital Associates LLC now owns 91,579 shares of the medical equipment provider’s stock valued at $2,671,000 after buying an additional 38,249 shares during the period. Knights of Columbus Asset Advisors LLC raised its stake in shares of Boston Scientific by 94.9% in the third quarter. Knights of Columbus Asset Advisors LLC now owns 38,600 shares of the medical equipment provider’s stock valued at $1,126,000 after buying an additional 18,800 shares during the period. LS Investment Advisors LLC raised its stake in shares of Boston Scientific by 5.8% in the third quarter. LS Investment Advisors LLC now owns 40,621 shares of the medical equipment provider’s stock valued at $1,185,000 after buying an additional 2,209 shares during the period. Finally, Chevy Chase Trust Holdings Inc. raised its stake in shares of Boston Scientific by 1.4% in the third quarter. Chevy Chase Trust Holdings Inc. now owns 1,197,587 shares of the medical equipment provider’s stock valued at $34,934,000 after buying an additional 16,992 shares during the period. 90.42% of the stock is currently owned by institutional investors and hedge funds.
BSX has been the topic of several research reports. BMO Capital Markets boosted their target price on Boston Scientific from $30.00 to $32.00 and gave the company an “outperform” rating in a research note on Friday, October 27th. Stifel Nicolaus restated a “buy” rating and issued a $32.00 target price on shares of Boston Scientific in a research note on Monday, September 25th. SunTrust Banks set a $33.00 target price on Boston Scientific and gave the company a “buy” rating in a research note on Monday, December 4th. Zacks Investment Research upgraded Boston Scientific from a “sell” rating to a “buy” rating and set a $33.00 target price on the stock in a research note on Friday, October 20th. Finally, Needham & Company LLC restated a “buy” rating and issued a $32.00 target price on shares of Boston Scientific in a research note on Tuesday, October 3rd. Two investment analysts have rated the stock with a sell rating, four have given a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Boston Scientific currently has a consensus rating of “Buy” and an average target price of $31.00.
Shares of Boston Scientific Corporation (NYSE BSX) opened at $27.65 on Monday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.50 and a current ratio of 0.72. Boston Scientific Corporation has a one year low of $23.29 and a one year high of $29.93. The stock has a market capitalization of $37,970.00, a price-to-earnings ratio of 45.33, a P/E/G ratio of 1.98 and a beta of 0.96.
Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.31. Boston Scientific had a return on equity of 23.60% and a net margin of 9.55%. The company had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.21 billion. During the same period in the previous year, the company posted $0.27 EPS. The firm’s revenue for the quarter was up 5.6% compared to the same quarter last year. research analysts anticipate that Boston Scientific Corporation will post 1.25 earnings per share for the current year.
In other Boston Scientific news, insider Valley Gold Master Fund L. Sun bought 408,006 shares of the firm’s stock in a transaction on Tuesday, November 28th. The shares were acquired at an average cost of $0.45 per share, for a total transaction of $183,602.70. Also, EVP Timothy A. Pratt sold 10,000 shares of the company’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $28.22, for a total value of $282,200.00. Following the completion of the transaction, the executive vice president now owns 164,681 shares in the company, valued at $4,647,297.82. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 96,585 shares of company stock worth $2,578,197. 0.74% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: “Boston Scientific Corporation (BSX) Shares Bought by State of Alaska Department of Revenue” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/01/22/boston-scientific-corporation-bsx-shares-bought-by-state-of-alaska-department-of-revenue.html.
Boston Scientific Profile
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.